Sign Up
Stories
BiVACOR Appoints New Chairman
Share
AI-Powered Raspberry Pi Stethoscope Inno...
Advanced Technology Saves Patient's Life
Attune Medical's Growth in Esophageal Te...
BiVACOR Welcomes New CEO and FDA Approva...
Biospectal OptiBP: A Revolutionary Blood...
CARMAT's 2024 Financial Calendar and Hea...
Overview
API
BiVACOR appoints Raymond W. Cohen as Chairman of the Board of Directors, leveraging his extensive experience in the life sciences industry. The company has received FDA approval for a clinical feasibility study of its BiVACOR Total Artificial Heart (TAH) for biventricular heart failure, aiming to address the global unmet need of patients with end-stage heart failure.
Ask a question
How does BiVACOR's mission to improve the quality of life for patients with heart failure align with broader healthcare trends and advancements?
How does the appointment of Raymond W. Cohen as Chairman of the Board of Directors impact BiVACOR's future direction and strategic initiatives?
What are the potential implications of the FDA approval for the BiVACOR Total Artificial Heart (TAH) on the medical device industry and patient care?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Sep 2023
Oct 2023
Nov 2023
Coverage